Labcorp Holdings Inc. (LH) Stock Forecast Oct. 16, 2026
Analysis updated on Oct. 16, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Labcorp Holdings Inc. (LH) stock forecast summary
On Oct. 16, 2026, LH is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
Labcorp Holdings Inc. is a large-cap company with a market capitalization of $25.79B. It ranks number 3 by market capitalization among the 29 Services-Medical Laboratories issuers in our coverage with a current forecast.
For LH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 39.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 15.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.8%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LH included.
Follow LH freeLH price chart and AI forecast
How LH ranks among 5172 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Labcorp Holdings Inc. (LH) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
Valuation & Market
| Metric | LH | Rank |
|---|---|---|
| Market Cap | $25.79B | 3/29 |
| P/E Ratio | 26.30x | 4/6 |
| P/B Ratio | 3.00x | 10/22 |
| Dividend Yield | 0.93% | – |
| EPS | $12.09 | – |
| Book Value/Share | $106.13 | – |
| Revenue/Share | $176.92 | – |
| FCF/Share | $14.24 | – |
Profitability & Margins
| Metric | LH | Rank |
|---|---|---|
| ROE | 11.7% | 3/14 |
| ROA | 5.4% | 4/20 |
| ROIC | 9.1% | 6/24 |
| Gross Margin | 28.9% | 7/16 |
| Operating Margin | 10.4% | 6/23 |
| Net Margin | 7.0% | 5/17 |
| EBT Margin | 8.5% | 6/23 |
| Tax Rate | 18.9% | – |
Financial Health
| Metric | LH | Rank |
|---|---|---|
| Current Ratio | 1.80x | 18/26 |
| Quick Ratio | 1.53x | 9/11 |
| D/E Ratio | 1.15x | 7/22 |
| Financial Leverage | 2.15x | 8/22 |
| Interest Coverage | 7.4x | 1/23 |
| Working Capital | $1.69B | 1/26 |
Cash Flow
| Metric | LH | Rank |
|---|---|---|
| Operating Cash Flow | $1.64B | 2/27 |
| Free Cash Flow | $1.16B | 2/17 |
| Capital Spending | -$483M | 16/17 |
| OCF Growth YoY | -3.3% | 6/7 |
| FCF Growth YoY | -8.4% | 3/5 |
| FCF/Sales | 8.1% | 5/16 |
| CapEx/Sales | 3.4% | 10/16 |
Operational Efficiency
| Metric | LH | Rank |
|---|---|---|
| Asset Turnover | 0.77x | 7/18 |
| Receivables Turnover | 6.1x | 13/19 |
| Inventory Turnover | 18.1x | 3/7 |
| Fixed Assets Turnover | 4.6x | 8/17 |
| Days Sales Outstanding | 60 days | 7/19 |
| Days Inventory | 20 days | 5/7 |
| Payables Period | 25 days | 12/14 |
| Cash Conversion Cycle | 55 days | 3/6 |
Income Statement
| Metric | LH | Rank |
|---|---|---|
| Total Revenue | $14.35B | 1/19 |
| Operating Income | $1.50B | 2/26 |
| Net Income | $1.00B | 2/20 |
| SG&A Expense | $2.22B | 1/20 |
| Cost of Goods Sold | $10.20B | 1/15 |
Dividend & Shareholder Information
| Metric | LH | Rank |
|---|---|---|
| Dividends Per Share | $2.95 | – |
| Payout Ratio | 24.4% | – |
| Shares Outstanding | 81M | – |
| Net Income Growth | 31.3% | 3/5 |
| EPS Growth | 33.1% | 3/6 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $3.81B | 20.6% of assets |
| Cash & Short-term Investments | $142M | 0.8% of assets |
| Accounts Receivable | $2.34B | 12.6% of assets |
| Inventory | $562M | 3.0% of assets |
| Total Liabilities | $9.91B | 53.5% of assets |
| Short-term Debt | $1.44B | 7.7% of assets |
LH quarterly financials and insider trading
Labcorp Holdings Inc. (LH) industry peers
Companies classified under the same SEC industry code as Labcorp Holdings Inc. (Services-Medical Laboratories): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| LH Labcorp Holdings Inc. | ▶ | $25.79B |
| NTRA Natera, Inc. | ▲ | $56.71B |
| DGX Quest Diagnostics Inc | ▼ | $25.94B |
| GH Guardant Health, Inc. | ▲ | $21.28B |
| CAI Caris Life Sciences, Inc. | ▲ | $8.64B |
| RDNT Radnet, Inc. | ▶ | $5.41B |
| GRAL Grail, Inc. | ▲ | $5.26B |
| BLLN Billiontoone, Inc. | ▲ | $4.63B |
| VCYT Veracyte, Inc. | ▲ | $3.47B |
| CDNA Caredx, Inc. | ▲ | $3.31B |
| CELC Celcuity Inc. | ▲ | $2.77B |
| FTRE Fortrea Holdings Inc. | ▶ | $2.14B |
| PSNL Personalis, Inc. | ▼ | $1.67B |
| FRNM Freenome, Inc. | ▶ | $1.26B |
| LMRI Lumexa Imaging Holdings, Inc. | ▶ | $1.04B |
| CSTL Castle Biosciences Inc | ▲ | $976M |
| FLGT Fulgent Genetics, Inc. | ▲ | $545M |
| BDSX Biodesix Inc | ▲ | $250M |
| XGN Exagen Inc. | ▲ | $187M |
| BNR Burning Rock Biotech Ltd | ▲ | $168M |
| SERA Sera Prognostics, Inc. | ▼ | $78M |
| MDXH Mdxhealth Sa | ▶ | $58M |
| CFOR Capforce Inc. | ▶ | $43M |
| AMS American Shared Hospital Services | ▼ | $9M |
| ADVB Advanced Biomed Inc. | ▶ | $7M |
| ACON Aclarion, Inc. | ▲ | $5M |
| BGLC Bionexus Gene Lab Corp | ▲ | $4M |
| LUDG Ludwig Enterprises, Inc. | ▶ | $670K |
| FCHS First Choice Healthcare Solutions, Inc. | ▶ | $260K |
| RNLXY Renalytix Plc | ▲ | N/A |
Where LH sits on the market map
Labcorp Holdings Inc. (LH) stock news
Loading...
Labcorp Holdings Inc. (LH) stock forecast FAQ
What is the Labcorp Holdings Inc. (LH) stock forecast?
On Oct. 16, 2026, LH is rated Neutral: its 90-day Alpha forecast sits in the middle 30% of the 5172 stocks scored that day.
How accurate are Labcorp Holdings Inc. stock predictions?
For LH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 39.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 15.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Labcorp Holdings Inc. forecasts updated?
Labcorp Holdings Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
Which companies are Labcorp Holdings Inc.'s industry peers?
30 issuers in our coverage, LH included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT), Grail, Inc. (GRAL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.